U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C5H11NO2S
Molecular Weight 149.211
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHIONINE

SMILES

CSCC[C@H](N)C(O)=O

InChI

InChIKey=FFEARJCKVFRZRR-BYPYZUCNSA-N
InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1

HIDE SMILES / InChI

Molecular Formula C5H11NO2S
Molecular Weight 149.211
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/cdi/methionine.html | http://www.rxlist.info/cons/me-500.html | https://www.ncbi.nlm.nih.gov/pubmed/5124307 | https://www.ncbi.nlm.nih.gov/pubmed/14505437

Methionine is an non-polar, aliphatic, essential α-amino acid that is used in the biosynthesis of proteins. High levels of methionine can be found in eggs, sesame seeds, Brazil nuts, fish, meats and some other plant seeds; methionine is also found in cereal grains. Most fruits and vegetables contain very little of it. Most legumes are also low in methionine. However, it is the combination of methionine and cystine which is considered for completeness of a protein. There is scientific evidence that restricting methionine consumption can increase lifespans in some animals. However, since methionine is an essential amino acid, it cannot be entirely removed from animals' diets without disease or death occurring over time. For example, rats fed a diet without methionine developed steatohepatitis (fatty liver), anemia and lost two thirds of their body weight over 5 weeks. Administration of methionine ameliorated the pathological consequences of methionine deprivation.

Originator

Sources: Journal of Biological Chemistry, Volume92, Pages 449-52, Journal, 1931

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MEONINE

Approved Use

It is used to make the urine more acidic. Making the urine more acidic helps to relieve skin irritation in incontinent (loss of bladder control) adults and diaper rash in infants. This medicine also helps to control strong urine odor.
Primary
Me-500

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.1 μg/mL
40 mg/kg single, oral
dose: 40 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHIONINE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
17.81 μg × h/mL
40 mg/kg single, oral
dose: 40 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHIONINE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.36 h
40 mg/kg single, oral
dose: 40 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHIONINE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
3 g 2 times / day multiple, oral
Studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, 31-62
Health Status: unhealthy
Age Group: 31-62
Sex: M+F
Sources:
Disc. AE: Gastrointestinal symptom NOS...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal symptom NOS (8.3%)
Sources:
3 g 2 times / day multiple, oral
Studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, 42.5
Health Status: unhealthy
Age Group: 42.5
Sex: M+F
Sources:
AEs

AEs

AESignificanceDosePopulation
Gastrointestinal symptom NOS 8.3%
Disc. AE
3 g 2 times / day multiple, oral
Studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, 31-62
Health Status: unhealthy
Age Group: 31-62
Sex: M+F
Sources:
PubMed

PubMed

TitleDatePubMed
Palladium(II) and platinum(II) complexes as synthetic peptidases.
2001
Novel mutations in the GALK1 gene in patients with galactokinase deficiency.
2001
Different usage of the glycosaminoglycan attachment sites of biglycan.
2001 Apr 20
Saccharomyces cerevisiae is capable of de Novo pantothenic acid biosynthesis involving a novel pathway of beta-alanine production from spermine.
2001 Apr 6
Bus, a bushy Arabidopsis CYP79F1 knockout mutant with abolished synthesis of short-chain aliphatic glucosinolates.
2001 Feb
The folate cycle and disease in humans.
2001 Feb
In situ kinetic characterization of methylthioadenosine transport by the adenosine transporter (P2) of the African Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense.
2001 Feb 15
Regulation of cell function by methionine oxidation and reduction.
2001 Feb 15
Trp 346 and Leu 352 residues in protective antigen are required for the expression of anthrax lethal toxin activity.
2001 Feb 16
Extracellular amino acid profiles in the paraventricular nucleus of the rat hypothalamus are influenced by diet composition.
2001 Feb 23
Orientations of Tyr 21 and Tyr 24 in the capsid of filamentous virus Ff determined by polarized Raman spectroscopy.
2001 Feb 6
Intestinal disappearance and mesenteric and portal appearance of amino acids in dairy cows fed ruminally protected methionine.
2001 Jan
Intestinal apical amino acid absorption during development of the pig.
2001 Jan
Intestinal aminooligopeptidase in diabetic BioBreed rat: altered posttranslational processing and trafficking.
2001 Jan
Characterization of promoter region and genomic structure of the murine and human genes encoding Src like adapter protein.
2001 Jan 10
Cloning and functional analysis of the Sry-related HMG box gene, Sox18.
2001 Jan 10
Analysis of the subsite specificity of rat insulysin using fluorogenic peptide substrates.
2001 Jan 12
Selective degradation of oxidized calmodulin by the 20 S proteasome.
2001 Jan 12
Sec63p and Kar2p are required for the translocation of SRP-dependent precursors into the yeast endoplasmic reticulum in vivo.
2001 Jan 15
Haem-linked interactions in horseradish peroxidase revealed by spectroscopic analysis of the Phe-221-->Met mutant.
2001 Jan 15
Thromboangiitis obliterans (Buerger's disease).
2001 Jan 18
Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after balloon injury.
2001 Jan 2
Comparison of Vif sequences from diverse geographical isolates of HIV type 1 and SIV(cpz) identifies substitutions common to subtype C isolates and extensive variation in a proposed nuclear transport inhibition signal.
2001 Jan 20
Electronic characterization of the oxidized state of the blue copper protein rusticyanin by 1H NMR: is the axial methionine the dominant influence for the high redox potential?
2001 Jan 23
Mapping the energy surface for the folding reaction of the coiled-coil peptide GCN4-p1.
2001 Jan 23
The additional methionine residue at the N-terminus of bacterially expressed human interleukin-2 affects the interaction between the N- and C-termini.
2001 Jan 30
Crystallization and preliminary X-ray crystallographic studies of recombinant human betaine-homocysteine S-methyltransferase.
2001 Mar
The effects of oral methionine and homocysteine on endothelial function.
2001 Mar
Evidence against oxidative stress as mechanism of endothelial dysfunction in methionine loading model.
2001 Mar
Relative reactivities of N-chloramines and hypochlorous acid with human plasma constituents.
2001 Mar 1
COMT-dependent protection of dopaminergic neurons by methionine, dimethionine and S-adenosylmethionine (SAM) against L-dopa toxicity in vitro.
2001 Mar 2
Impaired ATP synthase assembly associated with a mutation in the human ATP synthase subunit 6 gene.
2001 Mar 2
Transporters on demand: intrahepatic pools of canalicular ATP binding cassette transporters in rat liver.
2001 Mar 9
Sequence requirements for the N-methyl-D-aspartate receptor antagonist activity of conantokin-R.
2001 Mar 9
Uptake of tritiated thymidine, deoxyglucose and methionine in three lung cancer cell lines: deoxyglucose uptake mirrors tritiated thymidine uptake.
2001 Mar-Apr
Patents

Sample Use Guides

In Vivo Use Guide
Adults and teenagers—The usual dose is 200 milligrams (mg) three or four times a day. Children—The usual dose is the contents of 1 capsule (200 mg) added to a warm bottle of milk or formula in the evening, or added to a glass of juice or water.
Route of Administration: Oral
MCF-7 cells were obtained from American Type Culture Collection (Manassas, VA). Cells were cultured in a 5% CO~-humidified atmosphere at 37 OC in control medium, which consisted of Dulbecco's modified Eagle medium-F12 medium (1:1) supplemented with 5% bovine serum and 10 txg/ml insulin. Various concentrations (0.02, 0.2, 2, 5, and 10 g of methionine/L) were tested to determine the optimal level of methionine supplementation that causes the maximum inhibition of breast cancer cells. Cells were seeded in 96-well plates at a density of 1 • 10 a cells/well and grown in control medium for 24 h. The medium was then replaced with either control or methionine-supplemented treatment media as described above. Cell growth was assessed daily by the CellTiter 96 Aqueous One-Solution Cell Proliferation Assay reagent (Promega, Madison, WI). We found that cell growth was significantly suppressed by 5 to 10 g/L methionine on day 1, and no more growth was detected after 3 d of treatment.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:17:41 GMT 2025
Edited
by admin
on Mon Mar 31 18:17:41 GMT 2025
Record UNII
AE28F7PNPL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHIONINE
EP   HSDB   II   INCI   INN   MART.   MI   USAN   USP   VANDF   WHO-DD  
USAN   INN   INCI  
Official Name English
L-METHIONINE
FCC   USP-RS  
Preferred Name English
L-METHIONINE [FCC]
Common Name English
METHIONINE [HSDB]
Common Name English
L-METHIONINE [JAN]
Common Name English
METHIONINE [EP MONOGRAPH]
Common Name English
Methionine [WHO-DD]
Common Name English
(2S)-2-AMINO-4-(METHYLSULFANYL)BUTANOIC ACID
Systematic Name English
METHIONINE [USAN]
Common Name English
NSC-22946
Code English
METHIONINE [II]
Common Name English
METHIONINE [MI]
Common Name English
METHIONINE [MART.]
Common Name English
methionine [INN]
Common Name English
LEUCINE IMPURITY B [EP IMPURITY]
Common Name English
L-METHIONINE [USP-RS]
Common Name English
METHIONINE [USP MONOGRAPH]
Common Name English
METHIONINE [VANDF]
Common Name English
Classification Tree Code System Code
LOINC 47706-7
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 63380-0
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 56957-4
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 53397-6
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 53156-6
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 26963-9
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 17264-3
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
DSLD 171 (Number of products:32)
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 25959-8
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 47702-6
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 47701-8
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
DSLD 1779 (Number of products:2)
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
WHO-ATC V03AB26
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
DSLD 2065 (Number of products:1257)
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 27098-3
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
WHO-VATC QG04BA90
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 44338-2
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 2624-5
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 47703-4
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 15130-8
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 26844-1
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
FDA ORPHAN DRUG 91795
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 47700-0
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 25956-4
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 47704-2
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 22681-1
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 15145-6
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
NCI_THESAURUS C68442
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 2622-9
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 13405-6
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
WHO-VATC QV03AB26
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 20651-6
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 13772-9
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 47705-9
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 53161-6
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 2621-1
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 55943-5
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
CFR 21 CFR 172.320
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
WHO-VATC QA05BA90
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 32258-6
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 30063-2
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 13376-9
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 22716-5
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 27953-9
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 2623-7
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 25476-3
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 2620-3
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 32257-8
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
LOINC 22648-0
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
Code System Code Type Description
NSC
22946
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
CHEBI
49038
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
DAILYMED
AE28F7PNPL
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
CHEBI
64558
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
DRUG BANK
DB00134
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
EVMPD
SUB21984
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
INN
452
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
MESH
D008715
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
CHEBI
49037
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
RXCUI
6837
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY RxNorm
RS_ITEM_NUM
1411504
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
CHEBI
16044
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
CHEBI
16811
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
EVMPD
SUB08850MIG
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
MERCK INDEX
m7317
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY Merck Index
CAS
63-68-3
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
NCI_THESAURUS
C29600
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
DRUG CENTRAL
3347
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
ChEMBL
CHEMBL42336
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-562-9
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
HSDB
4317
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
CHEBI
57844
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
ChEMBL
CHEMBL274119
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
FDA UNII
AE28F7PNPL
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
EPA CompTox
DTXSID5040548
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
SMS_ID
100000092414
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
WIKIPEDIA
METHIONINE
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
PUBCHEM
6137
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
CHEBI
16643
Created by admin on Mon Mar 31 18:17:41 GMT 2025 , Edited by admin on Mon Mar 31 18:17:41 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
LABELED -> NON-LABELED
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
EP
IMPURITY -> PARENT
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (TLC)
EP
IMPURITY -> PARENT
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
EP
Related Record Type Details
ACTIVE MOIETY